Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Davis

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology in Drug Development|February 7, 2024
Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or HipKuan-Ju Lin, Kenneth C Turner, Hazem E Hassan, et al.
Clinical Pharmacology in Drug Development|June 23, 2021
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 DataPavel Kovalenko, Mohamed A Kamal, John D Davis, et al.
Journal of Pediatric and Adolescent Gynecology|June 5, 2009
Vaginal bleeding due to an infantile hemangioma in a 3-year-old girlM Gerard Jackson, Judith Simms-Cendan, Shireen Madani Sims, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 30, 2021
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumabMasood Khaksar Toroghi, Jim Bosley, Lyn M Powell, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
Journal of Clinical Pharmacology|September 11, 2023
Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 TrialYuhuan Wang, Jenny-Hoa Nguyen, Ruben D de Ruiter, et al.
Clinical Pharmacology in Drug Development|March 12, 2022
Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled SyringeYehuda Z Cohen, Xiaojia Zhang, Binfeng Xia, et al.
The AAPS Journal|April 1, 2015
Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9Nageshwar R Budha, Maya Leabman, Jin Y Jin, et al.
Clinical Pharmacology and Therapeutics|March 3, 2018
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving DupilumabJohn D Davis, Ashish Bansal, David Hassman, et al.
Clinical and Translational Science|September 15, 2021
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trialsMatthew P Kosloski, George D Kalliolias, Christine R Xu, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology in Drug Development|February 7, 2024
Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or HipKuan-Ju Lin, Kenneth C Turner, Hazem E Hassan, et al.
Clinical Pharmacology in Drug Development|June 23, 2021
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 DataPavel Kovalenko, Mohamed A Kamal, John D Davis, et al.
Journal of Pediatric and Adolescent Gynecology|June 5, 2009
Vaginal bleeding due to an infantile hemangioma in a 3-year-old girlM Gerard Jackson, Judith Simms-Cendan, Shireen Madani Sims, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 30, 2021
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumabMasood Khaksar Toroghi, Jim Bosley, Lyn M Powell, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
Journal of Clinical Pharmacology|September 11, 2023
Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 TrialYuhuan Wang, Jenny-Hoa Nguyen, Ruben D de Ruiter, et al.
Clinical Pharmacology in Drug Development|March 12, 2022
Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled SyringeYehuda Z Cohen, Xiaojia Zhang, Binfeng Xia, et al.
The AAPS Journal|April 1, 2015
Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9Nageshwar R Budha, Maya Leabman, Jin Y Jin, et al.
Clinical Pharmacology and Therapeutics|March 3, 2018
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving DupilumabJohn D Davis, Ashish Bansal, David Hassman, et al.
Clinical and Translational Science|September 15, 2021
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trialsMatthew P Kosloski, George D Kalliolias, Christine R Xu, et al.
Pageof 9